Stifel Financial’s Cabaletta Bio CABA Stock Holding History

Stifel Financial’s Portfolio CABA Stock Details CABA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-49,554	Closed	-$68.6K	–	3481
2025 Q1	$68.6K	Buy	49,554 +7,928	+19%	+$16.9K	﹤0.01%	3322
2024 Q4	$94.5K	Buy	+41,626	New	+$146K	﹤0.01%	3249

Other funds holding CABA

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HCM

Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Stifel Financial's CABA Position: Q2 2025 in Review

Stifel Financial sold out of Cabaletta Bio (CABA) in Q2 2025, closing a stake of 49,554 shares — an estimated $68.6K sold.

Stifel Financial first reported a position in CABA in Q4 2024 and held it in 2 quarters. The position peaked at $94.5K in Q4 2024. 86 funds tracked by Wall St. Rank hold CABA as of Q2 2025.

Stifel Financial reported no remaining Cabaletta Bio position as of Q2 2025 after selling out during the quarter.
Stifel Financial sold 49,554 Cabaletta Bio shares in Q2 2025, an estimated $68.6K.
Stifel Financial first reported a position in Cabaletta Bio in Q4 2024 and held it in 2 quarters.
Stifel Financial's Cabaletta Bio position peaked at $94.5K in Q4 2024.
86 funds tracked by Wall St. Rank held Cabaletta Bio as of Q2 2025.

Based on Stifel Financial's 13F filing for Q2 2025, filed 14 Aug 2025.